Suven Life Sciences Limited   Report issue

For profit Phase 1 Phase 2
Founded: Hyderabad India (1989)

Organization Overview

First Clinical Trial
2014
NCT02342041
First Marketed Drug
2012
malathion (ovide)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

SUVEN LIFE | Suven Life Sciences Limited | SUVEN PHARMS

Active Ingredients

Marketed Drugs (4)

calcium (2020)

chloroquine (2021)

glycopyrronium (robinul) (2020)

malathion (ovide) (2012)

Drugs in Phase 2 Trials (2)

masupirdine (2 trials)

suvn-g3031 (4 trials)

Drugs in Phase 1 Trials (2)

suvn-911 (2 trials)

suvn-d4010 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Cataplexy (Phase 2)

Cognition Disorders (Phase 1)

Depressive Disorder (Phase 1)

Depressive Disorder, Major (Phase 1)

Narcolepsy (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 10
  • # of Trial APIs: 4